Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249543 | 0.94 | — | — | |
| SCHEMBL16674069 | 0.82 | ACHE (0.60) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5249634 | 0.82 | ACHE (0.52) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5247780 | 0.82 | ACHE (0.52) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5244923 | 0.81 | ACHE (0.59) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5244892 | 0.79 | ACHE (0.68) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL13060419 | 0.78 | — | — | |
| SCHEMBL16673943 | 0.78 | ACHE (0.63) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL965762 | 0.78 | — | — | |
| SCHEMBL22358999 | 0.78 | ACHE (0.71) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498394-B2 | (Meth)acrylic and (meth)acrylamide monomers, polymerizable compositions, and polymers obtained | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-03-03 | — | — | US | disclosed |
| US-20060252900-A1 | (Meth)arcrylic and (meth)acrylamide monomers, polymerizable compositions, and polymers obtained | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2006-11-09 | — | — | US | disclosed |
| WO-2004077511-A2 | (METH)ACRYLIC AND (METH)ACRYLAMIDE MONOMERS, POLYMERIZABLE COMPOSITIONS, AND POLYMERS OBTAINED | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252900-A1 | (Meth)arcrylic and (meth)acrylamide monomers, polymerizable compositions, and polymers obtained | MMAB, MAT1A, MAT2A | ACHE 3480/4885CHRNB2 3281/4885CHRNB4 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.